Intelliheart tests in Amcal pharmacies
Friday, 13 June, 2008
IM Medical (ASX: IMI) has reached an exclusive agreement with Sigma Pharmaceuticals that will see the Intelliheart cardiac risk assessment tests sold through Sigma's Amcal network.
The Amcal network includes over 700 Amcal, Amcal Max and Guardian pharmacies throughout the country.
The product will initially be rolled out to over 200 pharmacies throughout Victoria in July. Stores in other states will begin stocking the product in the next few months.
Under the agreement Sigma has the right to produce and market other products using the Intelliheart brand name.
Intelliheart is the only widely available diagnostic which tests for both heart rate variability and arterial stiffness.
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
